Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Novo Nordisk said Thursday it was buying US biotech firm Akero Therapeutics, which is developing treatments for a number of metabolic diseases, for $4.7 billion. The Danish firm, the maker of ...

Novo Nordisk NOVO B announced plans on Oct. 9 to acquire Akero Therapeutics and its phase 3 FGF21 analog efruxifermin for USD 4.7 billion upfront and a potential additional USD 500 million contingent ...

CHICAGO, Oct 6 (Reuters) - A federal appeals court on Monday rejected Novo Nordisk's (NOVOb.CO), opens new tab challenge to the U.S. government’s program that gives its Medicare health insurance plan ...

Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Novo Nordisk is acquiring Akero Therapeutics for up to $5.2bn, aiming to diversify beyond semaglutide and strengthen its position in MASH and cirrhosis. The deal brings Akero's EFX, a promising FGF21 ...